Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Foscarnet
Drug ID BADD_D02421
Description An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Indications and Usage For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
Marketing Status approved
ATC Code J05AD01
DrugBank ID DB00529
KEGG ID D00579; D02267
MeSH ID D017245
PubChem ID 3415
TTD Drug ID D0OT0O
NDC Product Code Not Available
UNII 364P9RVW4X
Synonyms Foscarnet | Phosphonoformic Acid | Foscarnet Trisodium Salt | Foscarnet Calcium (2:3) Salt | Foscarnet Disodium Salt | Foscarnet Magnesium (2:3) Salt | Trisodium Phosphonoformate | Phosphonoformate | Foscarnet Sodium | Foscarnet Trilithium Salt | Foscarnet Tripotassium Salt | Foscarnet Sodium Hexahydrate | Foscavir | Foscarnet Barium (2:3) Salt | Foscarnet Manganese (2+) (2:3) Salt
Chemical Information
Molecular Formula CH3O5P
CAS Registry Number 4428-95-9
SMILES C(=O)(O)P(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.000621%
Acute respiratory distress syndrome10.02.01.067; 22.01.03.001; 24.03.02.0340.000423%
Altered state of consciousness17.02.04.001; 19.07.01.0030.000423%-
Cardiac arrest02.03.04.0010.000282%
Cardiac failure02.05.01.0010.000282%
Condition aggravated08.01.03.0040.000565%-
Cystitis haemorrhagic20.03.02.0030.000282%-
Dermatomyositis10.04.04.027; 15.05.01.002; 23.03.02.0010.000282%-
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000282%
Drug ineffective08.06.01.0060.001609%-
Dysuria20.02.02.0020.000282%
Electrolyte imbalance14.05.01.0020.000282%-
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.0090.000282%-
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.0470.000282%
Headache17.14.01.0010.000423%
Hepatic encephalopathy09.01.03.006; 17.13.01.0030.000282%-
Hepatic failure09.01.03.0020.000706%
Hypocalcaemia14.04.01.0040.001129%
Hypokalaemia14.05.03.0020.001270%
Hypomagnesaemia14.04.02.0010.000565%
Hypophosphataemia14.04.03.0010.000423%
Interstitial lung disease10.02.01.033; 22.01.02.0030.000282%-
Nephropathy toxic12.03.01.010; 20.05.03.0020.000282%-
Neuropathy peripheral17.09.03.0030.000423%-
Pancreatitis07.18.01.0010.000282%
Pancytopenia01.03.03.0030.000706%-
Paraesthesia17.02.06.005; 23.03.03.0940.000423%
Polyneuropathy17.09.03.0120.000282%-
Pulmonary oedema02.05.02.003; 22.01.03.0030.000282%
Pyrexia08.05.02.0030.000282%
The 1th Page    1 2    Next   Last    Total 2 Pages